CALCA and Miyoshi myopathy: CGRP receptor antagonists and anti-CGRP monoclonal antibodies (mAbs) have shown consistent efficacy and tolerability in the prevention of chronic or episodic migraine and are now approved for clinical use.[8–10] However, only a few studies have reported the use of these drugs in MM.